Page 2 - சிகிச்சை முடுக்குப்பொறி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சிகிச்சை முடுக்குப்பொறி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சிகிச்சை முடுக்குப்பொறி Today - Breaking & Trending Today

Bill Gates, Vaccine Monster | The New Republic

How Bill Gates Impeded Global
Access to Covid Vaccines
Through his hallowed foundation, the world’s de facto public health czar has been a stalwart defender of monopoly medicine.
Illustration by Kelsey Dake
On February 11, 2020, public health and infectious disease experts gathered
by the hundreds at the World Health Organization’s Geneva mothership. The official pronouncement of a pandemic was still a month out, but the
agency’s international brain trust knew enough to be worried. Burdened by a
sense of borrowed time, they spent two days furiously sketching an “R&D Blueprint”
in preparation for a world upended by the virus then known as 2019-nCoV. ....

New York , United States , United Kingdom , South Africa , North Korea , City Of , South Africans , South African , Thomas Cueni , Emma Walmsley , Donald Trump , Mark Suzman , Dylan Mohan Gray , Albert Bourla , Bill Gates , Kasia Russell , Peter Hotez , Emanuel Martin , Priti Patnaik , Al Gore , George Moose , James Love , Geneva Health Files , National Institute Of Allergy , Melinda Gates Foundation , A Fast Company ,

Investegate |Montreal Heart Institute Announcements | Montreal Heart Institute: Colchicine reduces the risk of COVID-19-related complications

Investegate announcements from Montreal Heart Institute, Colchicine reduces the risk of COVID-19-related complications ....

South Africa , United States , Sophie Desmarais , Jean Claude Tardif , Camille Turbide , Christy Maginn , Montreal Heart Institute , Us National Institutes Of Health , Research Center , Melinda Gates Foundation , Dacima Software Inc , Pharmascience Inc , Montreal Health Innovations Coordinating Center , Blood Institute , National Heart , Principal Investigator , South America , Dacima Software , Electronic Data Capture , Dacima Clinical Suite , Therapeutics Accelerator , Investegate Announcements , Investegate Company Announcements , Globe Newswire , Globenewswire And , ஒன்றுபட்டது மாநிலங்களில் ,

Colchicine reduces the risk of COVID-19-related complications

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Colchicine reduces the risk of COVID-19-related complications
Montreal Heart InstituteJanuary 23, 2021 GMT
MONTREAL, Jan. 22, 2021 (GLOBE NEWSWIRE) The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo. This result obtained for the global study population of 4488 patients approached statistical significance. The analysis of the 4159 patients in whom the diagnosis of COVID-19 was proven by a naso-pharyngeal PCR test has shown that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization compared to placebo. In these patients with a proven diagnosis of ....

South Africa , United States , Sophie Desmarais , Jean Claude Tardif , Camille Turbide , Christy Maginn , Montreal Heart Institute , Us National Institutes Of Health , Research Center , Melinda Gates Foundation , Dacima Software Inc , Pharmascience Inc , Montreal Health Innovations Coordinating Center , Blood Institute , National Heart , Principal Investigator , South America , Dacima Software , Electronic Data Capture , Dacima Clinical Suite , Therapeutics Accelerator , Products And Services , Coronavirus Pandemic , Product Testing , Diagnosis And Treatment , Globe Newswire ,

Colchicine reduces the risk of COVID-19-related complications Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients

Article content
MONTREAL, Jan. 22, 2021 (GLOBE NEWSWIRE) The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo. This result obtained for the global study population of 4488 patients approached statistical significance. The analysis of the 4159 patients in whom the diagnosis of COVID-19 was proven by a naso-pharyngeal PCR test has shown that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization compared to placebo. In these patients with a proven diagnosis of COVID-19, colchicine reduced hospitalizations by 25%, the need for mechanical ventilation by 50%, and deaths by 44%. This major scientific discovery makes colchicine the world’s first oral dr ....

South Africa , United States , Sophie Desmarais , Jean Claude Tardif , Camille Turbide , Christy Maginn , Montreal Heart Institute , Us National Institutes Of Health , Research Center , Melinda Gates Foundation , Dacima Software Inc , Pharmascience Inc , Montreal Health Innovations Coordinating Center , Blood Institute , National Heart , Principal Investigator , South America , Montreal Heart , Dacima Software , Electronic Data Capture , Dacima Clinical Suite , Therapeutics Accelerator , ஒன்றுபட்டது மாநிலங்களில் , சோஃபி டெஸ்மாரைஸ் , ஜீன் கிளாட் தாற்டிப் , கிறிஸ்டி ம்யாஜிந் ,

Protective immunity against SARS-CoV-2 could last eight months or more

Credit: Jenna Hambrick, La Jolla Institute for Immunology
LA JOLLA New data suggest that nearly all COVID-19 survivors have the immune cells necessary to fight re-infection.
The findings, based on analyses of blood samples from 188 COVID-19 patients, suggest that responses to the novel coronavirus, SARS-CoV-2, from all major players in the adaptive immune system, which learns to fight specific pathogens, can last for at least eight months after the onset of symptoms from the initial infection.
Our data suggest that the immune response is there and it stays, LJI Professor Alessandro Sette, Dr. Biol. Sci., who co-led the study with LJI Professor Shane Crotty, Ph.D., and LJI Research Assistant Professor Daniela Weiskopf, Ph.D. ....

Erica Ollmann Saphire , Kathrynm Hastie , Miyu Kato , Alba Grifoni , Bjoern Peters , Jose Mateus , April Frazier , Caterinae Faliti , Shane Crotty , Stephena Rawlings , Alessandro Sette , Jenniferm Dan , Viviana Simon , Esther Dawen Yu , Daveym Smith , Florian Krammer , Cohen Foundation , Collaborative Influenza Vaccine Innovation Centers , Melinda Gates Foundation , Research Assistant Professor Daniela Weiskopf , Infectious Diseases Division , Mary Tu Foundation , Assistant Professor Daniela Weiskopf , National Institutes , National Institute , Infectious Disease ,